1. Japan Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Sumitomo Pharma Co., Ltd.

Sumitomo Pharma Co., Ltd.

DNPUF
Sumitomo Pharma Co., Ltd.US flagOther OTC
8.41
USD
- -
- -
3.77BMarket Cap
Sumitomo Pharma Co., Ltd.
DNPUF
(Other OTC)

Recent

price

8.41

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
955.24
881.89
875.22
975.84
934.72
1,014.86
1,027.83
1,175.03
1,155.98
1,215.05
1,298.67
1,409.63
1,398.33
791.76
1,003.91
1,140.99
407.53
Revenue per Share
42.27
21.72
25.28
50.49
38.88
62.16
78.82
134.53
122.39
102.58
141.5
141.99
-187.55
-792.79
59.49
268.99
-622.25
Basic EPS, GAAP
115.51
99.5
100.4
71.45
45.02
99.86
14.31
204.04
90.1
82.5
314.11
44.66
-2.03
-648.45
8.73
- -
-187.98
Free Cash Flow per Basic Share
17.99
17.99
18
18
18
18
18
20
27.99
32.99
27.99
28
28
7.03
0.01
- -
0.02
Dividend per Share
821.98
769.33
776.61
802.56
822.25
877.82
956.88
1,053.2
1,143.22
1,207.49
1,336.74
1,350.67
763.67
-0.67
174.15
456.55
23.02
Book Value per Share
454.85
532.38
510.78
608.46
697.6
588.53
289.35
422.72
572.37
104.12
222.2
200.69
-332.12
-602.33
-504.52
-199.12
-640.04
Tangible Book Value per Share
397
397
397
397
397
397
397
397
397
397
397
397
397
397
397
397
397
Basic Weighted Avg Shares
379,529
350,384
347,732
387,709
371,370
403,205
408,357
466,838
459,267
482,732
515,952
560,035
555,544
314,558
398,832
453,294
161,916
Sales/Revenue/Turnover
34.41
5.82
7.2
10.87
6.27
9.16
9.87
18.89
12.6
17.24
13.8
10.76
-13.86
-112.8
7.45
23.18
-165.74
Operating Margin (%)
44,627
40,232
35,085
26,776
19,226
20,265
12,713
12,887
13,976
17,365
22,673
38,348
41,263
37,765
25,562
- -
19,106
Depreciation Expense
16,796
8,629
10,043
20,060
15,447
24,697
31,316
53,448
48,627
40,753
56,219
56,413
-74,512
-314,969
23,634
106,865
-247,228
Net Income, GAAP
32.95
47.15
44.69
42.2
54.23
37.57
26.8
37.02
25.24
57.21
52.69
51.06
- -
- -
- -
- -
- -
Effective Tax Rate (%)
4.43
2.46
2.89
5.17
4.16
6.13
7.67
11.45
10.59
8.44
10.9
10.07
-13.41
-100.13
5.93
23.58
-152.69
Profit Margin (%)
175,796
228,285
208,607
228,404
244,856
157,658
75,427
138,333
175,094
-132,408
181,648
221,148
9,166
-245,905
12,565
7,752
-174,588
Working Capital
93,000
118,000
95,000
85,000
50,000
28,000
10,000
30,940
27,980
25,020
263,859
243,963
244,128
133,367
258,982
179,056
133,430
LT Debt
323,983
319,227
349,248
398,540
451,021
389,594
412,268
452,723
498,138
635,860
648,178
673,569
406,782
156,136
169,479
292,467
114,244
Total Equity
17.46
2.3
3.01
5.02
2.04
4.57
6.15
11.05
8.17
4.74
3.54
3.11
- -
- -
- -
- -
- -
Return on Invested Capital (%)
3.76
2.02
2.48
4.93
3.84
6.22
7.51
12.49
10.26
6.85
8.76
8.45
- -
- -
- -
- -
- -
Return on Capital (%)
5.22
2.73
3.27
6.39
4.79
7.31
8.59
13.39
11.14
8.73
11.12
10.57
-17.74
- -
- -
85.3
-198.6
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
ST Debt
285,517
- -
255,950
LT Borrowings
133,367
- -
133,430
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
397
- -
397
Market Capitalization
143,534
139,535
231,294

Working Capital

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
Total Current Assets
269,569
- -
311,929
Cash, Cash Equivalents & STI
36,132
- -
115,911
Accounts Receivable, Net
81,023
- -
66,063
Inventories
115,350
- -
105,637
Total Current Liabilities
515,474
- -
486,517
Payables & Accruals
- -
- -
- -
ST Debt
285,517
- -
255,950
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.91%
-3.24%
72.57%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
44.59%
67.13%
352.17%
Sales/Revenue/Turnover
3.08%
0.96%
13.66%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
75,686
76,956
82,386
79,530
314,558
2025
- -
- -
- -
- -
398,832
2026
- -
- -
- -
- -
453,294

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-97.81
-72.68
-125.77
- -
-792.79
2025
- -
- -
- -
- -
59.49
2026
- -
- -
- -
- -
268.99

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
6.89
0.12
0.02
- -
7.03
2025
- -
- -
- -
- -
0.01
2026
- -
- -
- -
- -
- -
Similar Companies
H. Lundbeck A/S (HLUN-B.CO)
Charlotte's Web Holdings, Inc. (CWEB.TO)
Elanco Animal Health Inc (ELAT)
VISEN Pharmaceuticals (2561.HK)
Guardion Health Sciences, Inc. (GHSI)
iAnthus Capital Holdings, Inc. (IAN.CN)
Business
Sumitomo Pharma Co., Ltd. is a research and development-oriented pharmaceutical company engaged in the development, manufacture, and sale of pharmaceutical products focused on oncology, psychiatry, neurology, and regenerative medicine/cell therapy. The company offers a diverse portfolio including small molecule drugs, regenerative medicine and cell therapy products, pharmaceutical products for medical treatment, and advanced therapies targeting critical disease areas such as cancer, psychiatric and neurological disorders, and rare diseases. Sumitomo Pharma operates globally, with a significant footprint in Japan, North America, and Asia. Founded in 2005 and headquartered in Osaka, Japan, the company has recently expanded its global presence through strategic acquisitions and consolidations, notably acquiring all outstanding shares in Myovant Sciences in April 2023, thereby strengthening its biopharmaceutical capabilities and product pipeline in areas including oncology, urology, women’s health, and rare diseases. In 2024 and 2025, the company has advanced its regenerative medicine and cell therapy business, including clinical trials for iPS cell-derived therapies for conditions such as Parkinson’s disease, retinal pigment epithelium tear, and retinitis pigmentosa, with product sales beginning for RETHYMIC®, a regenerative medicine therapy for pediatric congenital athymia. Additionally, Sumitomo Pharma entered into an agreement transferring its Asia pharmaceutical business operations to Marubeni Corporation in 2025 to focus on accelerating growth in its core markets, notably in the U.S. with leading products such as Gemtesa, Orgovyx, and Myfembree, while continuing to develop novel oncology and regenerative medicine pipeline assets. The company is actively pursuing novel therapies in hematology, including investigational oral small molecules for myelofibrosis and acute leukemia, marked by recent clinical data presentations. Sumitomo Pharma’s strategic focus includes leveraging innovations in pharmaceuticals and regenerative medicine to enhance global healthcare and contribute to patient well-being worldwide.

Company News

APIChatGPT

  • businesswire.com

    Sumitomo Pharma America Achieves Key Patient Enrollment Milestone for Pivotal Phase 2 Study of Enzomenib in the Treatment of Relapsed/Refractory Acute Leukemia

  • seekingalpha.com

    Sumitomo Pharma Co., Ltd. (DNPUF) Discusses R&D Progress, Oncology Pipeline, and Advances in Regenerative Medicine and Vaccines Transcript

  • cnbc.com

    Sumitomo Pharma shares plunge 12% despite greenlight for Parkinson's treatment